How pharma could feel the pain of a recession

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

By Meagan Parrish • March 21, 2025

Vaccine makers face mRNA backlash as states seek further restrictions

A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

By Amy Baxter • March 19, 2025

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

The key factors shaping China’s biopharma boom

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

By Alexandra Pecci • March 19, 2025

Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

By Michael Gibney • March 13, 2025

IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

By Amy Baxter • March 12, 2025

Pricing transparency is in the spotlight — and that could be good news for drugmakers

An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

By Michael Gibney • March 11, 2025

As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges

Experts say cost and other barriers present challenges to returning to U.S. shores.

By Kelly Bilodeau • March 10, 2025

How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?

With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.

By Amy Baxter • March 7, 2025

The top 3 impacts of Trump’s health data purge

Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

By Michael Brady • March 6, 2025

Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

By Michael Gibney • Feb. 25, 2025

Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms

Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.

By Amy Baxter • Feb. 24, 2025

In FDA job cuts, experts see threat of far-reaching impact

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.

By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025

A look at Trump’s healthcare cuts — so far

How the federal workforce crackdown has impacted the agencies that oversee pharma and healthcare.

By Meagan Parrish • Feb. 21, 2025

Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma

The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive overhaul or incremental change.

By Michael Gibney • Feb. 11, 2025

Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions

While the 10% tariff on Chinese goods won’t have too much impact on branded drugs, generics are struggling to pivot.

By Kelly Bilodeau • Feb. 7, 2025

RFK Jr. will face these critical tests if confirmed as head of the HHS

After a Senate committee advanced President Trump’s nominee to lead HHS, Robert F. Kennedy Jr. is poised to secure the top job at the nation’s healthcare agency.

By Amy Baxter • Feb. 5, 2025

Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid

As President Trump and his cohorts plan to shut down the U.S. Agency for International Development, here’s what that could mean for global health and the drugmaking industry.

By Michael Gibney • Feb. 4, 2025

What should pharma make of the FDA going dark on DEI?

After a series of potent executive orders last week, the FDA removed draft guidance on diversity in clinical trials.

By Meagan Parrish • Feb. 4, 2025

Drugmakers prep for bird flu outbreak, despite continued low risk

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.

By Kelly Bilodeau • Feb. 3, 2025

Pharma’s forecast for 2025: Sowing seeds of a rebound

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

By Meagan Parrish • Jan. 31, 2025

Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge

NIH grants that help fund drug development were caught in the mix of confusing executive orders this week.

By Amy Baxter • Jan. 31, 2025

RFK Jr. faces reconciliation of past vaccine statements at Senate HHS hearing

“Are you supportive of these onesies?” Sen. Bernie Sanders asked Kennedy, pointing to infant clothing stamped with anti-vaccine slogans — and more from yesterday’s confirmation hearing.

By Michael Gibney • Jan. 30, 2025

A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?

Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

By Amy Baxter • Updated Feb. 4, 2025

Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt

As changes to the U.S. regulatory foundation take hold, pharmas need to change their strategies to keep innovation — and the bottom line — above the surface.

By Michael Gibney • Jan. 28, 2025

In pharma’s competitive climate, companies need evidence beyond clinical trials

Early planning and market research are crucial in an era of rising cost pressures.

By Kelly Bilodeau • Jan. 21, 2025